{
  "Anatomical Direction (Ov)": [], 
  "Bone System Location (At)": [], 
  "Cancer Histology Subtype (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1297, 
        1303
      ]
    }
  ], 
  "Cancer Histology Type (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1048, 
        1057
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1304, 
        1313
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1458, 
        1467
      ]
    }
  ], 
  "Clinical History Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1647, 
        1670
      ]
    }
  ], 
  "Comments Heading (At)": [], 
  "Final Diagnosis Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        974, 
        1001
      ]
    }
  ], 
  "Flow Cytometry Heading (At)": [], 
  "Internal X-reference (At)": [], 
  "Laterality (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        954, 
        958
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        960, 
        964
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1012, 
        1016
      ]
    }
  ], 
  "Lymphatic System Location (At)": [], 
  "Macroscopic/Gross Description Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        514, 
        543
      ]
    }
  ], 
  "Microscopic Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1797, 
        1832
      ]
    }
  ], 
  "Nature of Specimen Heading (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        908, 
        934
      ]
    }
  ], 
  "Negative Findings Phraseology (Ov)": [], 
  "Neoplasm Behaviour (Ov)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1031, 
        1039
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1314, 
        1321
      ]
    }
  ], 
  "Neoplasm Descriptive Grade (At)": [], 
  "Neoplasm Grade Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1338, 
        1339
      ]
    }
  ], 
  "Neoplasm Grade-Score Name (At)": [], 
  "Neoplasm Morphology (At)": [], 
  "Neoplasm Score Value (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1112, 
        1113
      ]
    }
  ], 
  "Neural System Location (At)": [], 
  "Organ/Body Structure (At)": [
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        939, 
        945
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        965, 
        971
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1004, 
        1010
      ]
    }, 
    {
      "__agreement__": "TRUE POSITIVE", 
      "__annotator__": "Model - 20180202_CDC_B1B2B4_5,Model - 20180209_CDC_B1B2B4B5_6", 
      "__extent": [
        1040, 
        1047
      ]
    }
  ], 
  "Positive Findings Phraseology (At)": [], 
  "Primary Origin of Neoplasm (At)": [], 
  "Relative Distance (Ov)": [], 
  "Relative Location (Ov)": [], 
  "Skin System Location (At)": [], 
  "Specimen Identifier (At)": [
    {
      "__annotator__": "Steven", 
      "__extent": [
        937, 
        938
      ], 
      "visible": ""
    }
  ], 
  "Specimen Tissue/Substance (At)": [], 
  "Supplementary Report Heading (At)": [], 
  "Synoptic Report Heading (At)": [], 
  "Vascular System Location (At)": [], 
  "__text": "MSH|^~\\&|PATHLAB_LIS|HOSPITAL 1^9999^MOH|PIMS|CCO|20160504135731|38CE6ED8ACDB4C887D219DFDD297C66675DE5485|ORU^R01|Q1908566641T3581844132|P|2.5|\nPID|1||J999999^^^^CMR^HOSPITAL 1&9999&MOH~J999999^^^^MRN^HOSPITAL 1&9999&MOH~9999999999&NV&ON^^^^JHN||XXXXXX^XXXXXXX^XXXX||99999999|M|||999 XXXXXXX XXXXX^^XXXXXXX^XXX^X9X9X9^999|||||||||||||||||||N|\nOBR|1||S-16-0018025|11529-5^Surgical Pathology Study Report^LN^P^Pathology^L|||20160425|||73714^XXXXXXXXXX^XXXXXX||||||||||N||20160504|||F|||||||99999^XXXXXX^XXXX|\n\n\n\n\n\n\n\nPath report.gross description\n\n\nThe specimen and patient identifiers are reviewed and verified.\nSpecimen: Unoriented, irregular piece of fibrofatty breast tissue (3.0 2.5 x 2.0 cm). \nMain findings: It contains a solid, well-circumscribed, tan nodule (1.5 x 1.5 x 1.5 cm).\nSection code (entirely submitted, surface inked): (A1-A5). \nGross examination by Erland Laylo. P.A 2016/04/27 15:01 /lp\n\n\nPath report.site of origin\n\n\nA Breast biopsy, left, Left Breast\n\n\nPath report.final diagnosis\n\n\nBreast, left, excision: \n- Invasive mammary carcinoma, no special type\n   - Estimated SBR Grade: 1/3 (Score 5/9)\n      - Nuclear Pleomorphism: 2/3\n      - Tubule Formation: 2/3\n      - Mitotic Score: 1/3 (2/10 HPFs; 0.50 field diameter)\n   - Lymphovascular space invasion: not identified\n   - Ductal carcinoma in situ: present (grade 2/3, solid pattern, without necrosis)\n   - Microcalcifications: present\n- ER/PR/Her2-neu: see Microscopic Description\n- carcinoma present at margin of excision, mutiple foci, specimen recieved unoriented\n- carcinoma invades skeletal muscle.\n\n*Case reviewed with Allison Osmond, M.D., Pathology Fellow AO/BW\n\n\nPath report.relevant Hx\n\n\nThe following information was submitted electronically by the ordering physician:\nExcision of Reccurance of Breast Cancer\n\n\nPath report.microscopic observation\n\n\nA:\nImmunohistochemistry for estrogen receptor protein: Positive: strong nuclear staining in 95 % of invasive carcinoma \nImmunohistochemistry for progesterone receptor protein: Positive: strong nuclear staining in 95 % of invasive carcinoma \nImmunohistochemistry for HER2/neu protein overexpression:  \n   SP3 - Negative: cytoplasmic membrane staining of weak intensity in <10 % of invasive carcinoma (1+) \n   A0485 - Negative (0) \n   Overall interpretation of HER2/neu protein overexpression: negative \n \nImmunohistochemical methodology:  \n   ER/PR method:  \n      EP1 and PgR636 antibodies; EnVision Flex/Flex+ detection. \n      Positive if nuclear staining of any intensity in >1% of invading cells (Harvey et al, JCO 17;5, 1474-81, 1999) \n   HER2 method:  \n      A0485 and SP3 antibodies; EnVision Flex/Flex+ detection. \n      Positive if circumferential membrane staining that is complete, intense in > 10% of the invasive tumor cells (3+). \n      Equivocal if circumferential membrane staining that is incomplete and/or weak/moderate and within > 10% of the invasive tumor cells; OR \n      complete and circumferential membrane staining that is intense and within <= 10% of the invasive tumor cells (2+). (Wolff et al., J. Clin. Oncol. 2013; 31(31): 3997-4013). \n   Control comment: control slides stain appropriately\n\n\n"
}